Cover ImageSALE
Market Research Report

Global Myelodysplastic Syndrome Therapeutics Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 665969
Published Content info 119 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Myelodysplastic Syndrome Therapeutics Market 2018-2022
Published: July 10, 2018 Content info: 119 Pages
Description

About Myelodysplastic Syndrome Therapeutics

Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.

Technavio's analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Myelodysplastic Syndrome Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Celgene
  • Otsuka
  • Novartis

Market driver

  • Improved prognostic classification of MDS through advanced technologies
  • For a full, detailed list, view our report

Market challenge

  • Inadequacies in treatment landscape of MDS
  • For a full, detailed list, view our report

Market trend

  • High incidence in older adult population
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR23344

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • MDS Pipeline

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION

  • Segmentation by ROA
  • Comparison by ROA
  • Oral drugs - Market size and forecast 2017-2022
  • Parenteral Drugs - Market size and forecast 2017-2022
  • Market opportunity by route of administration

PART 09: MARKET SEGMENTATION BY SUB-TYPE OF MDS

  • Segmentation by sub-type of MDS

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

  • High cost of disease-management
  • High incidence in older adult population

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Market positioning of vendors
  • Celgene
  • Otsuka
  • Novartis

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global oncology market
  • Exhibit 02: Parent market: The global oncology market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Drugs approved by US FDA for MDS
  • Exhibit 06: Drugs approved by European Medicines Agency (EMA) for MDS
  • Exhibit 07: MDS pipeline phase II development stage agents
  • Exhibit 08: MDS pipeline phase III development stage agents
  • Exhibit 09: Treatment Algorithm in MDS
  • Exhibit 10: Market definition - Inclusions and exclusions checklist
  • Exhibit 11: Market size 2017
  • Exhibit 12: Validation techniques employed for market sizing 2017
  • Exhibit 13: Global MDS therapeutics market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 14: Global MDS therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 15: Five forces analysis 2017
  • Exhibit 16: Five forces analysis 2022
  • Exhibit 17: Bargaining power of buyers
  • Exhibit 18: Bargaining power of suppliers
  • Exhibit 19: Threat of new entrants
  • Exhibit 20: Threat of substitutes
  • Exhibit 21: Threat of rivalry
  • Exhibit 22: Market condition - Five forces 2017
  • Exhibit 23: Global MDS therapeutics market by ROA - Market share 2017-2022 (%)
  • Exhibit 24: Comparison by ROA
  • Exhibit 25: Oral drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Oral drugs - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Parenteral drugs - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 28: Parenteral drugs - Year-over-year growth 2018-2022 (%)
  • Exhibit 29: Market opportunity by route of administration
  • Exhibit 30: Customer landscape
  • Exhibit 31: Global MDS therapeutics market by geography - Market share 2017-2022 (%)
  • Exhibit 32: Regional comparison
  • Exhibit 33: Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 35: Top 3 countries in Americas
  • Exhibit 36: EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 37: EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 38: Top 3 countries in EMEA
  • Exhibit 39: APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 40: APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 41: Top 3 countries in APAC
  • Exhibit 42: Market opportunity
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Vendor classification
  • Exhibit 48: Celgene overview
  • Exhibit 49: Celgene- Business segments
  • Exhibit 50: Celgene - Organizational developments
  • Exhibit 51: Celgene - Geographic focus
  • Exhibit 52: Celgene - Segment focus
  • Exhibit 53: Celgene - Key Offerings
  • Exhibit 54: Otsuka overview
  • Exhibit 55: Otsuka - Business segments
  • Exhibit 56: Otsuka - Organizational developments
  • Exhibit 57: Otsuka - Geographic focus
  • Exhibit 58: Otsuka - Segment focus
  • Exhibit 59: Otsuka- Key offerings
  • Exhibit 60: Novartis overview
  • Exhibit 61: Novartis - Business segments
  • Exhibit 62: Novartis - Organizational developments
  • Exhibit 63: Novartis - Geographic focus
  • Exhibit 64: Novartis - Segment focus
  • Exhibit 65: Novartis - Key offerings
Back to Top